Clin2
NCT07533929Possibly a fitNot yet recruiting

Liver enzyme changes in pregnant women with hepatitis B

Elevated Alanine AminotransferasePostpartum Chronic Hepatitis B Mothers

Part of Digestive system, Infections, Women’s health & pregnancy clinical trials.

This study tracks pregnant women with hepatitis B to understand why some develop elevated liver enzymes after delivery and what factors predict this. Findings could help doctors better monitor and care for mothers with hepatitis B during and after pregnancy.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
352 people
Ages
20 years to 40 years
Study type
Observational

Who can take part

  • Female, age 20–40 years old
  • Hepatitis B surface antigen (HBsAg) positive for at least 6 months
  • Normal liver enzyme (ALT) level at start: 40 U/L or lower
  • Currently pregnant (between 24 weeks of pregnancy and delivery)
  • If hepatitis B virus level is very high (>200,000 IU/ml), must take tenofovir (TDF) antiviral medication during pregnancy and stop it immediately after delivery
  • No other liver infections (hepatitis A, C, E), liver disease, heart/lung/kidney disease, or autoimmune conditions

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07542951Enrolling by invitation· Phase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B

This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.

Guangzhou, Guangdong
NCT07668934Enrolling by invitation· Phase 4
TAF for early and middle pregnancy with chronic hepatitis B

This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.

Guangzhou, Guangdong
NCT07054359Not yet recruiting
Hepatitis B treatment in pregnancy to prevent baby infection

This study compares two ways of treating hepatitis B in pregnant women to prevent passing the virus to their babies. It tests whether a standard universal treatment approach works better than a quick, point-of-care test-based strategy.

NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies

This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.

Guangzhou, Guangdong
NCT05853718Recruiting· Phase 4
Tenofovir treatment for hepatitis B during pregnancy

This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.

Hangzhou, Zhejiang
NCT07300345Not yet recruiting
Liver Health in Pregnant Women at Sohag Hospital

This study looks at how pregnancy affects the liver by checking levels of liver enzymes and bilirubin (jaundice-related substances) in pregnant women who have high levels. The goal is to better understand liver problems during pregnancy.

Hear when a new Elevated Alanine Aminotransferase trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.